IL1B and COVID-19: The anti-IL-1β antibody inhibitor canakinumab was also suggested as a viable therapeutic for COVID-19 patients (114); however, a recent clinical trial investigating its use showed that it did not significantly increase survival without invasive mechanical ventilation (115).